KRAS G12D inhibitors represent a significant advancement in the realm of targeted cancer therapy. Cancer treatments have long been a challenge, especially with mutations like KRAS G12D that promote tumor growth. Traditional therapies often fail against these mutations, causing frustration and improved urgency for effective solutions.

Signaling pathway drugs play a crucial role in modern cancer treatment. These drugs target specific communication pathways within cells, which can lead to tumor growth. Understanding how these drugs work can help patients and healthcare providers make informed decisions.

The global pharmaceutical intermediates market is set for significant expansion, with revenue expected to grow from USD 36,620.2 million in 2025 to USD 57,031.9 million by 2035, at a steady CAGR of 4.5%. In 2024, the market is valued at USD 35,081.4 million, highlighting the sector's accelerating momentum.

MRTX-1133 is one of the first potent, selective KRAS G12D inhibitors that binds noncovalently to the S-IIP of the active and inactive states of KRAS G12D [33]. Preclinical studies showed significant efficacy, with tumor regression in xenograft mouse models occurring in a dose-dependent manner [34].

Signal transducer and activator of transcription 5 (STAT5) is an attractive therapeutic target, but successful targeting of STAT5 has proved to be difficult. Here we report the development of AK-2292 as a first, potent and selective small-molecule degrader of both STAT5A and STAT5B isoforms.